Ann: 2023 Results webinar, page-57

By the way – these type of firms are very choosy in the programs they take on. And the due diligence carried out is exhaustive.

When Launch Therapeutics struck a funding deal with Opthea (ASX: OPT) in August 2022 for up to US$170 m (their very first partnership), 9 months was spent doing due diligence.

This is how Launch Therapeutics described itself in the OPT announcement at the time.

Launch Therapeutics (Launch Tx) is a clinical development company with a mission to disrupt the late-stage development paradigm, accelerate timelines to regulatory success and bring new medicines to patients faster. To deliver this, Launch Tx offers pharmaceutical and biotech partners a variety of innovative models that combine access to capital with deep drug development, medical, clinical operations, regulatory and commercialization expertise. These models include significant risk financing, clinical co-development and full in-licensing, all of which we believe offer partners an aligned and efficient approach to realizing the potential of late-stage clinical programs across any therapeutic area. Founded in 2022, Launch Tx is backed by leading investors, Carlyle and its life sciences franchise, Abingworth, and is led by a committed, experienced team with an enthusiastic passion to fulfil its mission. For more information, visit launchtx.com and follow us on LinkedIn